Tumor Markers Useful tool or part of the problem? Dr. Grant MacLean.

Slides:



Advertisements
Similar presentations
Diagnosis.
Advertisements

PET/CT in Oncology George Segall, M.D. Stanford University.
Audit of Impact of NICE guidelines for Ovarian Cancer Helen Losty Royal United Hospital Bath 17th November 2011.
Tumor Markers Lecture one By Dr. Reem Sallam. Objectives  To briefly introduce cancers, their incidence, some common terms, and staging system.  To.
Pelvic Masses & Ovarian Cancer. Differential diagnosis of pelvic masses Investigations and management Benign ovarian cysts Ovarian cancer.
Matthew Kilmurry, M.D. St. Mary’s General Hospital Grand River Hospital.
Doç.Dr. Jale Çoban Klinik Biyokimya Uzmanı
62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.
Tumor Markers Lecture one By Dr. Waheed Al-Harizi.
Prepare by: Ahmad Rsheed Presented to: Fatima Harzallah
Gestational Trophoblastic Neoplasia
Testicular cancer: current views Dr. M. Mangala MD (Kin); FRCS (Ireland); MMed (Wits); FCS (SA) Urology 38 th BMA CONGRESS.
Colorectal cancer Khayal AlKhayal MD,FRCSC
Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture By: Reem Sallam, MD, MSc, PhD.
Management of Gynaecological Cancers. Gynaecological Cancers in NSW 1180 new cases in % of all new cancer diagnoses Crude incidence rate 35.3 per.
Dr. Kenneth Lim Urology – MSU-COM POH McLaren Medical Center
© Copyright 2003 Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. PET in Breast Cancer Early detection of disease Precise Staging.
Eleni Galani Medical Oncologist
Tumor Markers: Clinical Usefulness
Neoplasms.
Case presentation- Ovarian cancer Agatha Stanek. Case presentation 32 year old female patient presents to clinic with bloating. A constant sense of abdominal.
© Copyright 2003 Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. PET in Colorectal Cancer Early detection of disease Precise Staging.
Terminology of Neoplasms and Tumors  Neoplasm - new growth  Tumor - swelling or neoplasm  Leukemia - malignant disease of bone marrow  Hematoma -
Towards Earlier Cancer Diagnosis Hamish Whitaker GP Tutor Guildford.
Malcolm Padwick MD FRCOG Gynaecology Cancer Surgeon
BY DR. KHANSA IQBAL SENIOR REGISTRAR GYNAE UNIT-II.
Quang Truong Mr. Kashub 2nd Session
Cholestatic liver diseases:
Unit of Gastrenterology Unit of Endocrinology THEAGENIO Hospital, Thessaloniki Metastatic neuroendocrine tumor of the jejunum-ileum.
Computed tomography scan of the abdomen shows a large cystic mass in the abdomen and pelvis without solid tissue or septations (measurement: 43×20×31-cm.
Prostate Cancer By: Kurt Rishel.
What are the usual sites of recurrence What are the usual sites of recurrence LocalLocal distantdistant Benefits Benefits Palliative chemo ± radiationPalliative.
In the name of God Isfahan medical school Shahnaz Aram MD.
MRS PC, 63YO WOMAN  Initially presented with chronic RIF pain  Found to have cholelithiasis, underwent a laparoscopic cholecystectomy  On the laparoscopy,
Tumor Biomarkers are high lightened Once Again Cancer Facts Cancer etiology Tumor Genetics Tumor MarkersLocation Classification Uses methods of detection.
Introduction to Cancer
 Identify different options of cancer therapy.  Most cancers are treated with a combination of approaches.
Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012.
PANCREATIC CANCER.
Tumor markers Present; by Dr. Andalib Isfahan Medical School
Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria Tumormarkers.
Targeting HER2 and Focusing on Patients With Gastric Cancer Jose Maria Vieitez, MD, PhD Assistant Professor of Oncology Department of Medical Oncology.
Tumor Markers.
Pancreatic Cancer L. Okolicsanyi G. Morana Pancreas Cancer l 2nd most common GI malignancy l 30,000 cases per year in US l 25,000 deaths per year l 4.
Grading And Staging Grading is based on the microscopic features of the cells which compose a tumor and is specific for the tumor type. Staging is based.
Liver Cancer  A leading cause of death in the world  Can be primary or a metastatic site  Seen more in other parts of the world  incidence African.
Principles of Surgical Oncology
Tumor Markers.
Synchronous Metastasis on Staging/Surveillance CT chest abdomen & Pelvis + CEA + MRI Liver /PET-CT Synchronous Metastasis on Staging/Surveillance CT chest.
Introduction and overview of CA19-9 CA19-9 is a tumour associated antigen found in the blood serum. CA 19-9 is also known as the Sialylated Lewis-antigen.
Mark Browning, M.D. IUSME.  22,000 Cases  14,000 Deaths  Overall Survival Rate is 35%  Survival Rate Depends on Stage.
Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture Dr. Usman Ghani.
Unit 6: Tumor markers. Introduction… Cancer is the second leading cause of death in North America, accounting for > 2.7 million deaths annually Although.
Oncology 2016 Mark D. Browning, M.D. ’77 Thyroid & Gastric Cancer
Metastatic Tumors of Ovary. METASTATIC TUMOR FROM BREAST CANCER both ovaries replaced by pale, rather nodular tumor, with breast cancer cells arranged.
Supraclavicular metastasis from urothelial bladder carcinoma: A case report S. Farmahan, T. Mirza, P. Ameerally Oral Maxillofacial Department, Northampton.
Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture Dr. Usman Ghani.
Kidney Cancer – All You Need to Know!
Case. Kreem is 53 year old man who is quite healthy with no previous illness. He has noticed changes in his bowel habits for the last few months, with.
Common pitfall in Oncology Luangyot Thongthieang, MD MEDICAL ONCOLOGY UNIT INTERNAL MEDICINE, KHONKAEN HOSPITAL.
Tumor markers 1111.
SMDT SMDT SMDT Synchronous Metastasis on Staging/Surveillance
SURGICAL ONCOLOGY AND TUMOR MARKERS
Consultant Medical Oncologist
Ovarian tumor markers Associate Professor Fariba Behnamfar
Bronchial Carcinoma Part 2
Prostate Cancer Dr .Gehan Mohamed.
Tumor Marker Tests.
Pancreatic Cancer What you need to know to be able to educate your patients and their families.
STOMACH CANCER BY DR: ALI ALWAILY/MD.
Presentation transcript:

Tumor Markers Useful tool or part of the problem? Dr. Grant MacLean

Glycoconjugates on the cell surface involved in adhesion, motility, metastasis can induce immune response expressed early in malignant transformation shed by cancer cells into serum

Monoclonal antibodies can be developed and used to detect these mucin antigens on the cancer cell surface or in the serum

Pathologists can now help us with diagnostic dilemmas Eg: Adeno ca, Unknown primary profile: TTF1, CK-7, CK20

Focus on Serum Tumor Markers esp: CEA CA 125 CA 19.9 also AFP, BHCG, PSA, CA15-3

Jen had presented with a pelvic mass. Ca 125 = 1000 Lap: Fallopian tube ca (Adeno Ca) With chemo: Ca 125 down to 10 (N<37)

Jen 9 months later Anxious, fatigued Ca 125 = 200 Now frightened Diagnosis? Plan?

Gary presents with weight loss and jaundice. CT scan: Gastric outline blurred, possible small mass in head of pancreas, possible small lesions in liver CEA = 20 (N<4) CA 19.9 = 1700 (N<37) Diagnosis? Plan?

screening diagnosis monitoring therapy remission follow-up

Anxious patients seek screening for: early diagnosis reassurance Some angry patients want to know “why was I not screened?”

CA 125 for Screening for Ovarian Cancer? FDA approval based on prediction of persistent ov ca at second look laparotomy 50% at 2 nd look lap with residual disease had negative CA % with Stage I disease normal serum CA ,283 women screened, 486 laps, to detect 5 invasive cas and 8 borderline tumors

CEA to screen for colon cancer, or relapse? Elevated in smokers Elevated in other cancers and benign disease Normal in 85% of patients with poorly differentiated cancer at presentation Only a small percentage have resectable disease Is the patient fit for partial hepatectomy?

Tumor Markers – some key facts: Lack of specificity Cancer heterogeneity False negatives Benign diseases positive CA 125 or CEA Smokers have raised CEA Many men (20-40% !?) die with, not from, prostate ca.

Screening: Is a negative reassuring? What does a positive indicate? What is the lead time? Can we treat it better if we find it early? Can we manage the anxiety we create?

Finding it early: PSA – do we need to treat? Is the lead time useful? CEA – small % have resectable disease In the patient otherwise fit enough to withstand the next steps? Living with the fear – and who will manage the anxiety?

Diagnosis: CA 125 +ve CEA +ve CA 19-9 What does it mean? Where is the primary?

Serum tumor markers may be a helpful piece of the puzzle but are seldom diagnostic Exceptions: AFP, BHCG, PSA

James, male, mid 30’s: - supra-clavicular lymph node - cough Clinically NAD except dull lung base CXR: pleural effusion.

James: CEAN AFPN BHCG300

Response to therapy? Early rise Fall usually means response beware heterogeneity “normal” does not mean remission palliative therapy – treat the symptom or the number?

Stella presented with abdominal swelling. “Limited lap” – “widespread ovarian ca” CA 125 = 300 falling to 80 with chemo Yet the abdominal mass is increasing!?

Most valuable uses of serum tumor marker: Are we using a useful therapy? Is this toxicity justifiable? Not all symptoms are cancer progression

Wendy had been on chemotherapy for Stage III ovarian cancer. CA 125 = 350 normal after 3 treatments Prior to 5 th chemo: abdominal pain, vomiting, no bowel movement for 3 days. Diagnosis? Plan?

At the end of therapy – beware the misleading Does not mean cure Does not mean complete remission May not even mean improvement If we use the number to reassure, we have to manage the anxiety with the rising number “normal”

Beware the “mysteries” Elevated marker with NED eg: BHCG with creatinine elevated Elevated marker with no cancer eg: CA125 or CEA Multiple markers elevated Marker falling, mass increasing There is a role for clinical judgement!

Follow-up monitoring: o If useful salvage therapy eg: CEA to detect solitary resectable met o If useful lead-time, and useful therapy eg: germ cell cas o But it can create anxiety false reassurance false hope

And the dilemma – what next?

Serum Tumor Markers - When most helpful o Gestational Trophoblastic Neoplasia o Chemotherapy of Germ cell cas o Monitoring pts with germ cell cas o Monitoring chemotherapy for ovarian ca o Seeking surgically resectable relapse

Serum Tumor Markers - When not helpful oProvoking anxiety o“Palliative chemotherapy” oTreat the symptom not the number oThe false reassurance of “normal”

Serum Tumor Markers highlight communication gaps oDoes the patient understand? oDoes the Oncologist understand? oIs the Oncologist accessible to the family physicians who knows the patient best, and who wonders “why?” or “what next”?

Gary: Had obstructive jaundice after stenting: CA 19.9 = 1700 normal.

Jen on clinical exam had diffuse Lymphadenopathy.  Infectious mononucleosis On recovery, Ca 125 normal (200 20).

Serum Tumor Markers A help? or a problem?